Emory University is one of 13 organizations that has joined the partner network as an inaugural group.
“We recognize that historically male-dominated and hierarchical environments such as academia, including medicine, can be fertile ground for sexual harassing behaviors,” says Carolyn Meltzer, MD, who is the chief diversity and inclusion officer at Emory’s School of Medicine and the university’s representative in the partner network. “My colleagues and I at Emory look forward to continuing our work on mitigating systemic gender bias and inequity as a member institution of the partner network, and filtering those efforts to a local level in Atlanta.”
The Pew Charitable Trusts
In March, nearly 40 individuals from across the country will meet with their legislators to urge Congress to take bipartisan action to prioritize the battle against antibiotic resistance: a looming global health threat that threatens the future of modern medicine. As part of The Pew Charitable Trusts’ Stand Up to Superbugs initiative, this year’s ambassadors include health care professionals, public health officials, scientists, farmers and ranchers, veterinarians, superbug survivors, and people who have lost loved ones to an antibiotic-resistant infection. They will meet virtually with federal agency leaders and members of Congress to share their superbug stories and expertise, and urge increased commitment and momentum to preserve the effectiveness of existing antibiotics and develop urgently needed new ones.
Best Health Degrees Releases National Rankings of Radiation Sciences Master s Programs prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Global Proteomics Partnering Terms and Agreements Analysis Report 2020
News provided by
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Proteomics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Clinical laboratories prepare for coronavirus variants
Adam Bonislawski, 360Dx
NEW
YORK
– As new variants of SARS-CoV-2 continue to emerge, clinical labs are having to develop new and evolve existing approaches to test for the virus.
While existing molecular tests appear to be capable of detecting the new UK and South Africa SARS-Cov-2 strains that have been the focus of much recent attention and concern, the appearance of these and other variants could require changes in labs testing processes and the development of better tools for monitoring the presence of relevant variants in the patients they serve.
The most immediate concern from a lab s perspective is that the mutations that characterize major SARS-CoV-2 variants may make molecular or antigen tests for detecting the virus less effective by altering the regions of RNA or protein these tests target.